Literature DB >> 22770237

Damage control and its costs: BM failure in Fanconi anemia stems from overactive p53/p21.

Bogdan Dumitriu1, Neal S Young.   

Abstract

Despite having well-characterized disease-associated mutations, the mechanisms underlying the progressive bone marrow failure and cancer susceptibility of Fanconi anemia have been unclear. In this issue of Cell Stem Cell, Ceccaldi et al. identify an overactive p53/p21 stress response and cell cycle arrest as an underlying cause that starts during fetal development.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22770237      PMCID： PMC3402214          DOI： 10.1016/j.stem.2012.06.013

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  7 in total

1.  Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.

Authors:  Raphael Ceccaldi; Kalindi Parmar; Enguerran Mouly; Marc Delord; Jung Min Kim; Marie Regairaz; Marika Pla; Nadia Vasquez; Qing-Shuo Zhang; Corinne Pondarre; Régis Peffault de Latour; Eliane Gluckman; Marina Cavazzana-Calvo; Thierry Leblanc; Jérôme Larghero; Markus Grompe; Gérard Socié; Alan D D'Andrea; Jean Soulier
Journal:  Cell Stem Cell       Date:  2012-06-07       Impact factor: 24.633

2.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 3.  Ribosomopathies: human disorders of ribosome dysfunction.

Authors:  Anupama Narla; Benjamin L Ebert
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

Review 4.  Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML.

Authors:  Andrzej Rochowski; Susan B Olson; Todd A Alonzo; Robert B Gerbing; Beverly J Lange; Blanche P Alter
Journal:  Pediatr Blood Cancer       Date:  2012-04-19       Impact factor: 3.167

Review 5.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

Review 6.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 7.  How the fanconi anemia pathway guards the genome.

Authors:  George-Lucian Moldovan; Alan D D'Andrea
Journal:  Annu Rev Genet       Date:  2009       Impact factor: 16.830
  7 in total
  2 in total

1.  mRNA deadenylation and telomere disease.

Authors:  Philip J Mason; Monica Bessler
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

2.  Studies in an Early Development Window Unveils a Severe HSC Defect in both Murine and Human Fanconi Anemia.

Authors:  Carine Domenech; Loïc Maillard; Alix Rousseau; Fabien Guidez; Laurence Petit; Marika Pla; Denis Clay; Fabien Guimiot; Sandra Sanfilippo; Sebastien Jacques; Pierre de la Grange; Noémie Robil; Jean Soulier; Michèle Souyri
Journal:  Stem Cell Reports       Date:  2018-10-25       Impact factor: 7.765
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.